{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_6946450_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"171-863-931-799-506","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11855,"type":"PATENT","title":"University of Montpellier Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":11808,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8467,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:univ* AND Montpellier. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1289
Search Applicants and Owners separately:univ* AND Montpellier. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1289
or a pharmaceutically acceptable salt thereof,\n
wherein R is selected from the group consisting of H, mono, di or tri phosphate, an amino acid acyl residue, acyl, alkyl, and a stabilized phosphate prodrug."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the compound is \n\n
or a phannaceutically acceptable salt thereof."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the R is a monophosphate."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the R is a diphosphate."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the R is a triphosphate."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the R is an amino acid acyl residue."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the R is acyl."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the R is alkyl."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the R is a stabilized phosphate prodrug."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the compound is administered in a pharmaceutically acceptable carrier."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the pharmaceutically acceptable carrier is suitable for oral delivery."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the pharmaceutically acceptable carrier is suitable for intravenous delivery."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the pharmaceutically acceptable carrier is suitable for parenteral delivery."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the pharmaceutically acceptable carrier is suitable for intradermal delivery."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the pharmaceutically acceptable carrier is suitabie for subcutaneous delivery."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the pharmaceutically acceptable carrier is suitable for topical delivery."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the compound is in the form of a dosage unit."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 17, wherein the dosage unit contains 10 to 1500 mg of the compound."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 17 or 18, wherein the dosage unit is a tablet or capsule."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["A method for treating a human infected with hepatitis B virus comprising administering an effective amount of the β-L-nucleoside: \n\n
or a pharmaceutically acceptable salt or thereof, in alternation or combination with one or more other anti-hepatitis agents,\n
wherein R is selected from the group consisting of H, mono, di or tri phosphate, an amino acid acyl residue, acyl, ailcyl, and a stabilized phosphate prodrug."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the anti-hepatitis agent is selected from the group consisting of β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC), cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxatbiolane (FTC), βL-2″-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU), β-D-2,6-diaminopurine dioxolane (DAPD), famciclovir, penciclovir, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclo-pentyl]-6H-purin-6-one (entecavir, BMS-200475), 9-[2-(phosphono-methoxy)ethyl]-adenine (PMEA, adefovir, dipivoxil); 9-((1R,2R,3S)-2,3-bis(hydroxyinethyl)cyclo-butyl)guanine (lobucavir), ganciclovir, and ribavirin."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the anti-hepatitis agent is β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC)."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the anti-hepatitis agent is cis-2-hydroxymcthyl-5-(5-fluorocytosin-1-yl)-1,3-oxatbiolane (FTC)."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the anti-hepatitis agent is L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU)."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the anti-hepatitis agent is β-D-2,6-diaminopurine dioxolane (DAPD)."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the anti-hepatitis agent is famicilovir."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the anti-hepatitis agent is penciclovir."],"number":27,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the anti-hepatitis agent is 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclo-pentyl]-6H-purin-6-one (entecavir, BMS-200475)."],"number":28,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the anti-hepatitis agent is 9-[2-(phosphono-methoxy)ethyl]-adenine (PMEA, adefovir, dipivoxil)."],"number":29,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the anti-hepatitis agent is 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclo-butyl)guanine (lobucavir)."],"number":30,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the anti-hepatitis agent is ganciclovir."],"number":31,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the anti-hepatitis agent is ribavirin."],"number":32,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the compound is administered in a pharmaceutically acceptable carrier."],"number":33,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the pharmaceutically acceptable carrier is suitable for oral delivery."],"number":34,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the pharmaceutically acceptable carrier is suitable for intravenous delivery."],"number":35,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the pharmaceutically acceptable carrier is suitable for parentcral delivery."],"number":36,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the pharmaceutically acceptable carrier is suitable for intradermal delivery."],"number":37,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the pharmaceutically acceptable carrier is suitable for subcutaneous delivery."],"number":38,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the pharmaceutically acceptable carrier is suitable for topical delivery."],"number":39,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the compound is in the form of a dosage unit."],"number":40,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 40, wherein the dosage unit contains 10 to 1500 mg of the compound."],"number":41,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 40 and 41, wherein the dosage unit is a tablet or capsule."],"number":42,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical composition for treating a human infected with hepatitis B virus comprising an effective amount of the B-L-nucleoside: \n\n
or a pharmaceutically acceptable salt or thereof,\n
wherein R is selected from the group consisting of H, mono, di or tri phosphate, an amino acid acyl residue, acyl, alkyl, and a stabilized phosphate prodrug;\n
with one or more other anti-hepatitis agents; optionally in a pharmaceutically acceptable carrier."],"number":43,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 43, wherein the β-L-nucleoside is \n\n
or a pharmaceutically acceptable salt thereof."],"number":44,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according claim 43, wherein the compound is the form of a dosage unit."],"number":45,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 45, wherein the dosage unit contains 10 to 1500 mg of the compound."],"number":46,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according claim 43, wherein the composition is administered in a pharmaceutically acceptable carrier."],"number":47,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according claim 43, wherein the pharmaceutically acceptable carrier is suitable for oral delivery."],"number":48,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according claim 43, wherein the pharmaceutically acceptable carrier is suitable for intravenous delivery."],"number":49,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according claim 43, wherein the pharmaceutically acceptable carrier is suitable for parenteral delivery."],"number":50,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according claim 43, wherein the pharmaceutically acceptable carrier is suitable for intradermal delivery."],"number":51,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according claim 43, wherein the pharmaceutically acceptable carrier is suitable for subcutaneous delivery."],"number":52,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according claim 43, wherein the pharmaceutically acceptable carder is suitable for topical delivery."],"number":53,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the R is a monophosphate."],"number":54,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the R is a diphospbate."],"number":55,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the R is a triphosphate."],"number":56,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the R is an amino acid acyl residue."],"number":57,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the R is acyl."],"number":58,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the R is alkyl."],"number":59,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein the R is a stabilized phosphate prodrug."],"number":60,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 43, wherein the R is a monophosphate."],"number":61,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 43, wherein the R is a diphosphate."],"number":62,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 43, wherein the R is a triphosphate."],"number":63,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 43, wherein the R is an amino acid acyl residue."],"number":64,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 43, wherein the R is acyl."],"number":65,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to ciaim 43, wherein the R is alkyl."],"number":66,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 43, wherein the R is a stabilized phosphate prodrug."],"number":67,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 45 or 46, wherein the dosage unit is a tablet or capsule."],"number":68,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 43, wherein the anti-hepatitis agent is selected from the group consisting of β-L-2-hydroxymcthyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC), cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC), β-L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU), β-D-2,6-diaminopurine dioxolane (DAPD), famciclovir, penciclovir, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclo-pentyl]-6H-purin-6-one (entecavir, BMS-200475), 9-[2-(phosphono-methoxy)ethyl]-adenine (PMEA, adefovir, dipivoxil); 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclo-butyl)guanine (lobucavir), ganciclovir, and ribavirin."],"number":69,"annotation":false,"claim":true,"title":false},{"lines":["The phannaceutical composition according to claim 43, wherein the anti-hepatitis agent is β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC)."],"number":70,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 43, wherein the anti-hepatitis agent is cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC)."],"number":71,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 43, wherein the anti-hepatitis agent is L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU)."],"number":72,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 43, wherein the anti-hepatitis agent is β-D-2,6-diaminopurine dioxolane (DAPD)."],"number":73,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 43, wherein the anti-hepatitis agent is famicilovir."],"number":74,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 43, wherein the anti-hepatitis agent is penciclovir."],"number":75,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 43, wherein the anti-hepatitis agent is 2-amino-1,9dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylene-cyclopentyl]-6H-purin-6-one (entecavir, BMS-200475)."],"number":76,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 43, wherein the anti-hepatitis agent is 9-[2-(phosphono-methoxy)ethy]-adenine (PMEA, adefovir, dipivoxil)."],"number":77,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 43, wherein the anti-hepatitis agent is 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclo-butyl)guanine (lobucavir)."],"number":78,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 43, wherein the anti-hepatitis agent is ganciclovir."],"number":79,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 43, wherein the anti-hepatitis agent is ribavirin."],"number":80,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 20, wherein the β-L-nucleoside is \n\n
or a pharmaceutically acceptable salt thereof."],"number":81,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}